RecruitingMenopause-related Hot Flashes
Finding Links Between Hot flASHes and CardioVascular Disease
Eligible age
40–65 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Sponsor: Massachusetts General Hospital
You may qualify if…
- ✓ Age 40-65 years
- ✓ Peri- and post-menopausal women (STRAW -1 to +1)
- ✓ Moderate or high vasmotor symptom burden
- ✓ Cardiometabolic disease (as evidenced by ≥ 2 of the following):
- ✓ Obesity (body mass index ≥ 30 kg/m2)
- ✓ Elevated waist circumference (≥ 88 cm)
- ✓ Elevated triglycerides (≥ 150 mg/dL or drug treatment)
- ✓ Reduced HDL-cholesterol (\<50 mg/dL or drug treatment)
You may not qualify if…
- ✕ Inability to provide informed consent or comply with study protocol
- ✕ Major comorbidities: cancer, end-stage renal (eGFR \<45 mL/min/1.73 m2), liver or lung disease
- ✕ Concomitant use of strong or moderate cytochrome P450 3A4 inhibitors
- ✕ Elevated liver function tests (ALT, AST, and/or total bilirubin ≥2x ULN)
- ✕ Undiagnosed uterine bleeding over past 6 months
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT07077395 · last updated 2026-05-20